Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
By L. Jayaram, M. Pizzichini, Richard J. Cook, L. Boulet, C. Lemière, E. Pizzichini, A. Cartier, P. Hussack, Charles H. Goldsmith, M. Laviolette and 2 more. European Respiratory Journal, 2006
634 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/b3b52815158be6cf13c09f72d00e0f2e93e74f28
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. (2009, background): “Corticosteroid reduction studies have consistently shown that a raised sputum eosinophil count is predictive of the development of an exacerbation (212, 277, 282, 289), and management strategies aimed at normalizing sputum eosinophil counts have been associated with up to 60% reduction in severe ast”
- A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. (2007, background): “It had no influence on the frequencyofnoneosinophilicexacerbations,whichwerethemost common exacerbations ( 26 ).”
- A summary of the new GINA strategy: a roadmap to asthma control (2015, background): “Most exacerbations are characterised by increased inflammation [60, 61]; studies with doubling ICS comprise most of the strong evidence base that continues to support recommendations for asthma self-management and written asthma action plans [62]; action plans which include both increased ICS…”